Introduction
Ocular tumors, though relatively rare, present significant clinical challenges, often leading to severe vision impairment or mortality. Understanding the pathogenesis and etiology of these conditions—ranging from pediatric retinoblastoma to adult uveal melanoma—is critical for developing effective diagnostic and therapeutic strategies. However, research has been historically limited by a shortage of high-quality human eye tissue and the inability of animal models to fully replicate human tumor biology.
To address these gaps, researchers at Xiangya Hospital have established a specialized ocular tumor biobank. This facility, the first of its kind in China, serves as a bridge between basic science and clinical application by providing standardized, well-annotated biospecimens for translational research.
Standardized Biobanking Workflow
The value of a biobank lies not just in its storage capacity but in the rigor of its collection and processing protocols. The Xiangya Ocular Tumor Bank operates under strict Standardized Operating Protocols (SOPs) to ensure the biological integrity of every sample.
The workflow encompasses four primary stages:
- Participant Recruitment: Patients suspected of or diagnosed with ocular tumors scheduled for surgery are informed and provide consent.
- Biological Specimen Processing: Tissue samples are preserved in liquid nitrogen immediately following surgery. Blood samples are processed within 30 minutes to separate plasma and whole blood components.
- Data Integration: Clinical variables, including demographics, imaging, and histopathology, are linked to physical samples via a digital management system.
- Research Sharing: A formal application and agreement process allows researchers to access these resources for pathological and translational studies.
Characterization of the Biobank Cohort
Between December 2018 and January 2020, the biobank collected 846 samples from 92 clinical cases, covering 21 distinct types of eye tumors. The collection includes 356 whole blood samples (42.1%), 324 plasma samples (38.3%), and 166 tissue samples (19.6%).
The cohort demonstrates a diverse demographic and diagnostic range. Age distribution shows that 50% of patients were between 31 and 60 years old, while 33% were 61 or older. The most prevalent conditions in the bank include basal cell carcinoma, lymphoma, and choroidal melanoma, alongside several undiagnosed or rare eye diseases.
Clinical Insights and Predictors of Malignancy
Beyond acting as a repository, the biobank's integrated data allowed for significant clinical analysis. Using multivariate logistic regression, the researchers identified key predictors of tumor malignancy:
- The "Proptosis Paradox": Interestingly, proptosis (bulging of the eye) was identified as a protective factor against malignancy in this specific cohort (B = -2.534; P = 0.001). This suggests that benign orbital masses were more likely to present with visible bulging than malignant ones in this population.
- Gender and Age: Gender was a significant predictor (B = 1.599; P = 0.025), with males exhibiting a higher prevalence of malignant tumors (87.5%). Furthermore, malignant tumors were more common in older patients (mean age 50.9) compared to those with benign tumors (mean age 41.5).
- Laterality: Tumors were slightly more frequent in the left eye (56%) and were overwhelmingly unilateral (95%).
Future Directions
While the biobank is in its early operational phase, it provides a robust foundation for future research. The current limitations, such as a single-center sample source and the need for greater public awareness regarding biobanking, are being addressed. Future plans include expanding into a multi-center network and utilizing the preserved samples to develop patient-derived tumor xenografts (PDX) and organoids. These "mini-tumors" will allow for real-time drug sensitivity testing, moving closer to the goal of personalized medicine for ocular tumor patients.
Summary updated